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Medication-related osteonecrosis of the jaw (MRONJ) is a serious adverse reaction of antiresorptive and antiangiogenic agents; it
is a potentially painful and debilitating condition that can considerably affect the quality of life of patients. Furthermore, even if its
epidemiology and pathogenesis have still not been fully clarified, several risk factors related to MRONJ have been recognized
in prevention protocols. Three main risk factors are as follows: (i) the type of ONJ-related medications: antiresorptive (e.g.,
Bisphosphonates, Denosumab) and antiangiogenic drugs (e.g., Bevacizumab, Sunitinib); (ii) the category of patient at MRONJ
risk: cancer versus non-cancer patient; (iii) the typologies and timing of dental treatments (e.g., before, during, or after the drug
administration). The aim of this paper is to describe the new paradigm by the Italian Society of Oral Pathology and Medicine
(SIPMO) on preventive dental management in patients at risk of MRONJ, prior to and during/after the administration of the
aforementioned ONJ-related drugs. In reducing the risk of MRONJ, dentists and oral hygienists are key figures in applying a
correct protocol of primary prevention for pre-treatment and in-treatment patients. However, the necessity of a multidisciplinary
standardized approach, with a sustained dialogue among specialists involved, should be always adopted in order to improve the
efficacy of preventive strategies and to ameliorate the patient’s quality of life.
1. Introduction
Medication-related osteonecrosis of the jaw (MRONJ) is a
relatively rare but potentially serious and debilitating compli-
cation. It consists of progressive bone destruction in the max-
illofacial area of patients exposed to the treatment with drugs
associated with the risk of ONJ, in the absence of a previous
radiation treatment [1–4]. The diagnosis of MRONJ is based
on the patient's pathological and pharmacological history and
on the clinical and radiological features of progressive bone
destruction (both exposed and not exposed) [1, 5].
MRONJ epidemiology and pathogenesis are still unclear;
however, in recent years, notable progress has been made
regarding the prevention of MRONJ by studying local risk
factors (e.g., presence of infective, dental-periodontal, and/or
peri-implant disease) in patients at risk of MRONJ and by
planning dental procedures [1, 5–9].
Primary prevention, whose main aim is the elimination
of oral and dental risk factors, is targeted at restoring and/
or maintaining good oral health and reducing the risk of an
onset of pathological conditions or any other negative event.
This approach has the greatest impact when aimed at protect-
ing constantly the patient’s oral health, which is at risk of MR
ONJ by virtue of controlling local related risk factors [6, 9].
Subsequent to the initial reporting of MRONJ, fifteen
years ago, attention has been focused on the association
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between dental extraction and adverse event in patients who
were already being treated with ONJ-related drugs [10–12].
More recently, the presence of infection at dental-periodontal
and peri-implant locations has been underlined as being
one of the main local risk factors of developing MRONJ,
often being the main reason of surgical procedures of dental
extraction or implant removal [1, 5, 13]. The link between
periodontal disease and the development of MRONJ has
been widely demonstrated, and the spreading of bacteria via
the periodontal pockets is one of the main mechanisms for
transmitting infection throughout the alveolar bone. Indeed,
it is not only the presence of Porphyromonas gingivalis in the
periodontal pockets but also IgG products which probably
promote the development of MRONJ. The concurrent action
of P. gingivalis and IgG products would appear to increase
bone remodeling and contemporaneously produce pro-
inflammatory effects, thereby reducing the healing process
of periodontal tissue and encouraging the development of
MRONJ.Therefore, a severe periodontitiswill be determinant
for a poor prognosis for the teeth, for whom the only resolu-
tion is extraction; the latter has already been discussed as a
further trigger for the developing of MRONJ [1, 7, 8, 14–19].
Many studies have demonstrated how, prior to com-
mencing treatment with ONJ-related drugs, dental screening
and treatments of oral diseases can significantly reduce the
occurrence of this adverse event [9, 20–22]. Already in
2009, Dimopoulos et al. underlined the importance of dental
management in patients eligible for treatment with ONJ-
related drugs; this primary preventive measure subsequently
produced a reduction by one-third of the incidence of
MRONJ in the enrolled patients [20]. Similar results have also
been obtained from other research groups, which highlighted
the crucial role played by the physician and the dentist in
the primary prevention [9, 21–23]. It is the responsibility of
the physician to provide all relevant information regarding
the risk of developing MRONJ for patients who are about to
commence treatmentwith antiresorptive (AR) and/or antian-
giogenic (AA) drugs. Moreover, it is also the physicians’ duty
to advise the patients about the relevance of an examination
by an oral health specialist with the aim of assessing the
necessity for preventive dental management. This should
be performed prior to commencing, during and also after
the treatment with ONJ-related drugs, in order to eliminate
any infective outbreaks of MRONJ [14, 24, 25]. It is the
responsibility of the dentist to accurately assess risk factors
leading to the development of MRONJ and suggest a strategy
for removing these factors. The dentist must also stress the
importance ofmaintaining effective dental hygiene, including
regular check-ups, for the patient. Both are necessary for
maintaining oral health, reducing the outbreak of MRONJ,
and/or detecting possible signs of the early symptoms of this
disease.
2. Variables of Patients at Risk of MRONJ
When planning primary prevention measures, every special-
ist assigned to the care and maintenance of oral health must
bear in mind three variables related to the assessment of the
risk of MRONJ.
2.1. The Activity of ONJ-Related Drugs: Antiresorptive and
Antiangiogenic Drugs. Drugs involved in the etiopathogen-
esis of MRONJ belong basically to two main categories:
those with a mainly antiresorptive property and those with
mainly antiangiogenic property. The AR drugs includes the
following:
(a) Bisphosphonates (BPs), synthetic analogues of pyro-
phosphates, which firmly bind to the hydroxyapatite
and reduce bone metabolism/remodeling. They are
long half-life medications, which constitute a deter-
mining variable for their residual power in a “non-
active” form in bone tissue after treatment has been
interrupted. Indeed, the half-life of BPs in circulation
is quite short, ranging from 30 minutes to 2 hours;
however, once they have been incorporated into bone
tissue, they can persist more than 10 years, depending
on the skeletal turnover time [25].
(b) Denosumab, a monoclonal human IgG2 antibody
that highly binds the receptor activator of nuclear
factor-kB ligand (RANK-L), blocks the osteoclast
maturation, function, and survival. It has a half-life
of 25–32 days [26, 27].
Of the drugs related to a risk of MRONJ with a main AA
activity, the most common are Vascular Endothelial Growth
Factor (VEGF) inhibitors (e.g., Bevacizumab), tyrosine-
kinase inhibitors (TKIs) (e.g., Sunitinib), and themammalian
target of Rapamycin (mTOR) inhibitors (e.g., Everolimus)
[3]. AA drugs are generally indicated only for the treatment
of oncological pathologies, by inhibiting the various mech-
anisms involved in tumour neoangiogenesis. Moreover, as
is the case with Denosumab, these drugs do not tend to
accumulate in the bone, and they have a well-known half-life,
which varies on the basis of the molecule (from 30 hours for
Everolimus to 20 days for Bevacizumab) [3].
2.2. The Categories of Patients at Risk: Cancer or Non-cancer.
On the basis of epidemiological data regarding the onset
of MRONJ, the risk is greater for cancer patients, who are
probably contemporaneously exposed to a high number of
MRONJ risk factors [1, 5, 13]. Indeed, there is a frequency
of adverse event between 0.2% and 6.7% in cancer patients
exposed to ONJ-related drugs, while the risk of developing
MRONJ in patients affected by osteometabolic diseases, such
as osteoporosis, is very low, with a prevalence between 0%
and 0.4% [5]. However, due to the huge number of patients
in the world affected by osteometabolic diseases, in terms of
frequency, approximately 40% of patients affected byMRONJ
are non-cancer patients [28].
2.3. Typologies and Timing of Dental Treatments . The pri-
mary purpose of preventive dental approach is the detection
and management of local risk factors related to MRONJ
(Table 1). Due to the risk/benefit ratio of dental procedures
and the risk of MRONJ, it is useful to distinguish three
typologies of dental treatments: (i) indicated, which are
necessary to prevent the risk of MRONJ; (ii) possible, which
are considered irrelevant in regard to the risk of MRONJ; (iii)
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contraindicated, which are associated with a recognized risk
of MRONJ.
This distinction will be better detailed in the following
paragraphs also with respect to patients' categories (cancer
versus non-cancer patients) and to ONJ-related drugs expo-
sure time.About the timing of dental procedures, patients can
be divided into two categories:
If the patient has never taken ONJ-related drugs, also
called in the pre-treatment phase, the patient’s oral health
must be precisely assessed by clinical and radiographic
examinations (mandatory for cancer patients), in order to
evaluate the patient’s dental-periodontal status and to plane
the adequate dental therapies compatible with systemic dis-
eases and the oncologist/physician’s opinion.
If the patient has already been exposed to ONJ-related
drugs, hereafter defined as the in-treatment phase, this
patient will be included in an assessment program of oral
health, the aim of which is to obtain and maintain as low as
possible the level of local risk factors for MRONJ.
It will be necessary to continually remind the patient of
the necessity both of maintaining effective oral hygiene at
home, via counselling strategies, and of monitoring early
clinical signs or symptoms of MRONJ. Dental procedures
for the patient (both cancer and non-cancer) in pre-treat-
ment and in-treatment phases will now be discussed in
order to enhance our understanding of this topic. Moreover,
invasive and non-invasive dental procedures will be also
differentiated on the basis of above mentioned distinction
(indicated, possible, contraindicated) (see Tables 2 and 3).
Of great assistance in this regard is the use of leaflets, such
as those which can be downloaded from https://www.unipa
.it/dipartimenti/di.chir.on.s./.content/documenti/ONJ-Leaflet-
SIPMO-by-Di-Fede-Campisi20-02-17.pdf. Additionally, the
app DoctOral provides an open-access consultation of
guided paths and recommendations regarding the dental
management of patients at risk of MRONJ; it is free
available both for android (https://play.google.com/store/
apps/details?id=com.olgadifede.olgapp&hl=it) and iOS sys-
tem (https://itunes.apple.com/us/app/doctoral/id1071070334
?l=it&ls=1&mt=8) [29].
3. Cancer Patients in the Pre-treatment Phase
In the pre-treatment phase, cancer patients with good oral
healthmust be informed andmade aware of the risks inherent
ofMRONJ and the necessity of being enrolled onto a program
with a 4-month follow-up, in order to monitor the status of
the hard and soft tissues. Moreover, the patient should be
encouraged to follow specific measures regarding secondary
prevention (early recognition of the disease) and be informed
about oral hygiene at home via counselling.
In cancer patients with tooth with poor or hopeless
prognosis or other dental-periodontal infection, it would
be desirable to defer the commencing of ONJ-related drugs
after the tissue involved in any invasive dental treatment has
healed. This includes at least the healing period of the soft
tissue, which is usually approximately 45–60 days, prior to
commencing AR/AA cancer treatment. For all other non-
invasive dental procedures whose outcome is reliable, it is
Table 1: Oral risk factors of MRONJ [1].
Oral risk factors
(i) Dental/periodontal infection
(ii) Peri-implantitis
(iii) Unfitting removable denture
Oral surgeries
(i) Dental extraction
(ii) Dental implant surgery
(iii) Endodontic surgery
(iv) Periodontal surgery
(v) Regenerative bone procedures
Anatomical conditions
(i) Torus and exostosis
(ii) Pronounced mylohyoid ridge
not necessary to defer cancer treatment. If cancer treatment
cannot be delayed and invasive dental procedures are needed,
it will be necessary to consider the patient as already being
in treatment phase. Thereafter, the protocols of medical and
surgical prophylaxis must be applied (see Section 5) [14, 25].
In greater detail, dentoalveolar surgeries are considered
to be indicated invasive dental procedures; it would be
convenient to reduce to a minimum any bone manipulation
and encourage primary intention healing.
Other invasive procedures (e.g., implant surgery, pre-
implant bone surgery, and mucogingival surgery) are con-
traindicated, since these are not aimed at the elimination of
infection and they have often a rehabilitation/aesthetic aim;
moreover, anyway these procedures will have an undefined
long-term risk of developingMRONJ after the administration
of ONJ-related drugs [14, 25, 26]. Dental treatments in cancer
patients in the pre-treatment phase are described in Table 2.
4. Non-cancer Patients in
the Pre-treatment Phase
Similarly, in this group of patients the primary objective is to
maintain and/or reestablish as soon as possible an acceptable
level of oral health, possibly before the administration of AR
drugs or within its first six months [14]. If the patient presents
with good oral health, it is beneficial to plan a six-month
follow-up examination in order to maintain the primary
prevention program.
In general, in a given non-cancer patient in the pre-
treatment phase, surgical and non-surgical dental procedures
are classified as indicated if regarding the treatment of
infective conditions (e.g., dental-alveolar surgery, surgical
and non-surgical endodontics, and surgical and non-surgical
periodontics). All elective procedures (e.g., prosthetic reha-
bilitation with/without dental implant, or orthodontic treat-
ment) are classified as possible with unknown or indefinable
low risk ofMRONJ. Dental treatments in non-cancer patients
in the pre-treatment phase are described in Table 2.
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Table 2: Main dental treatments with respect to patients’ categories in the pre-treatment phase with drugs related to ONJ.
Dental procedures on patients in the pre-treatment phase Cancer patients Non-cancer patients
Non-Surgical Procedures
Restorative dentistry Indicated Indicated
Endodontic treatment Indicated Indicated
Orthodontic treatment Possible Possible
Periodontal treatments: oral hygiene and non-surgical
treatments Indicated Indicated
Prosthesis Possible Possible
Surgical Procedures
Dentoalveolar surgery Indicated∗ Indicated
Preimplant bone surgery Contraindicated Possible‰
Dental implant surgery Contraindicated Possible‰
Periodontal/endodontic surgery Indicated§ Indicated§
∗Advisable to wait for wound healing (4–6 weeks) before initiating antiresorptive or antiangiogenic treatment for cancer therapy. When treatment with ONJ-
related drugs cannot be deferred, dentoalveolar surgery is indicated; in this case, the surgical protocol and medical treatment of oncological patients already
in-treatment with MRONJ-related drugs will also be performed. §To Perform only if any infective processes cannot be treated via periodontal/endodontic,
non-invasive treatment. ‰Advise the patient that the risk of MRONJ is indefinable in the long term.
Table 3: Main dental treatments in patients in-treatment phase with drugs related to ONJ.
Dental procedures on patients in-treatment phase Cancer patients Non-cancer patients
Category A Category B
Non-Surgical Procedures
Restorative dentistry Indicated Indicated Indicated
Endodontic treatment Indicated Indicated Indicated
Orthodontic treatment Possible Possible Possible
Periodontal treatments: oral hygiene and non-surgical
treatments
Indicated
(every 4 months) Indicated Indicated
Prosthesis Possible Possible Possible
Surgical Procedures
Dentoalveolar surgery Indicated Indicated Indicated
Preimplant bone surgery Contraindicated Possiblef Possible∗f‰
Dental implant surgery Contraindicated Possiblef Possible∗f‰
Periodontal/endodontic surgery Indicated§ Indicated Indicated§
∘Follow the surgical protocol + adapt the flaps, avoid of tension and suture in order to prioritize healing of the wound. §Perform only if any infective processes
cannot be treated with non-invasive periodontal/endodontic procedures. fAdvise the patient of an indefinable risk of MRONJ in the long term. ‰Advise the
patient of an indefinable risk of MRONJ in the short term.
5. Cancer Patients in Treatment Phase
From the first assumption of ONJ-related drugs for treating
cancer, the patient is considered to be at a high risk of
developing MRONJ [1, 5, 13, 14, 25, 27]. This is due to the
contemporaneous presence of known, multiple risk factors.
Surgical procedures which are necessary for eliminating
infective outbreaks of MRONJ are defined as indicated for
cancer patients in-treatment in presence of dental diseases
which cannot otherwise be resolved [1, 14].
The protocol regarding the dental extractions in cancer
patients at risk of MRONJ promoted by the Italian Society
of Oral and Maxillofacial Surgery (SICMF) and the Italian
Society of Oral Pathology and Medicine (SIPMO) combines
a medical prophylaxis with strictly surgical procedures. An
example of a standardized protocol for dental extractions
expects amedical prophylaxis that includes a 0.12% chlorhex-
idine (CHX) antiseptic mouthwash to be used at home 3
times a day, starting from 7 days prior to the planned dental
procedure, associated with an antibiotic therapy (e.g., Ampi-
cillin/Sulbactam im and Metronidazole per os) that must be
administered from the day before the intervention and for
at least 6 days following intervention. During the surgical
procedures, it is advisable to use local anesthesia without
adrenaline, to perform a full thickness flap, to gently remove
the tooth, to do the alveoloplasty of the postextraction site
(if necessary), and to apply a tension-free soft tissue closure,
to promote the healing by first intention[26]. Moreover,
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the use of ultrasound surgical equipment is preferable for
bone manipulation, even if, currently, conventional dental
instruments do not seem to increase the risk of MRONJ,
notwithstanding their more invasive nature [14, 30, 31].
The post-operative medical therapy will be accompanied
by a topical one, CHX mouthwash (3 times a day for 15
days), and growth-promoting treatment, as gel containing
hyaluronic acid (three times per day for 15 days) [14, 26].
Sutures can be removed between the seventh and tenth
day after intervention. Thereafter, periodic clinical check-up
should continue with an accurate time schedule (at 3, 6, and
12 months) during the first year of follow-up.
When several dental extractions are necessary, it would
be desirable to proceed one tooth at a time, particularly when
ONJ-related drugs have not been suspended. Recently, surgi-
cal proposals have been considered, which also deploy a low-
level, Nd:YAG laser and/or autologous platelet concentrates
(APCs) [32, 33].The application of APCs [34] with enhanced
stability (e.g., plasma rich in growth factor (PRGF) and
leucocyte-platelet-rich fibrin (L-PRF)) is yielding promising
results in reducing the incidence of MRONJ following a
dental extraction, thereby reducing the operating time and
the extent of necessary surgery mucocele [34, 35].
When inflammatory-infective processes may be treated
with periodontal and/or endodontic surgical procedures, the
clinician should apply the same recommendations regarding
dental extractions, and this also concerns medical prophy-
laxis and minimum bone manipulation [14].
The risk of developing MRONJ in in-treatment cancer
patient undergoing dental implants is not only in the long
term but it particularly increases in the short term.Therefore,
dental implants are contraindicated, given the high degree
of bone manipulation which is necessary for positioning the
implant fixtures. Moreover, it can be added that the systemic
health condition of a cancer patient could facilitate the rapid
onset of a peri-implantitis, an additional great risk factor of
MRONJ. Up to date, there are no published studies regard-
ing the execution of pre-implant surgical treatment (e.g.,
guided bone regeneration) on in-treatment cancer patients.
Notwithstanding a note of caution, it is the opinion of the
authors that procedures relating to pre-implant treatment
should be avoided in these patients, as well as the dental
implant placement [1, 5, 14, 36].
All non-invasive dental treatments (e.g., restorative ) are
not only considered as indicated but also of the utmost impor-
tance in reducing the spreading of infective processes [14, 37].
Notwithstanding this, some simple precautions prior to and
during the dental examination should be taken: provide an
antiseptic mouthwash to reduce the bacterial load in the
oral cavity; do not use vasoconstricting anaesthetic; always
work in isolation using a rubber dam, paying attention to the
correct position of the clamps of the dam to avoid trauma to
the oral mucosa. Moreover, during endodontic treatments, it
is essential to avoid exceeding the limits of the root canal with
endodontic instruments and root canal filling material [37].
As a non-invasive dental treatment, orthodontics is clas-
sified as an elective treatment and it is thus considered a
possible, in absence of MRONJ cases published related to it.
However, it has been suggested that orthodontic movements,
which cause an increase in alveolar bone remodeling, in the
cancer patients in-treatment may encourage the accumu-
lation of drugs in the jawbone [38–40]. However, it must
be underlined that cancer patient being treated with ONJ-
related drugs will rarely request orthodontic treatment [14,
16, 39, 40].
Non-surgical periodontal therapy is strongly indicated
and it should be carefully planned in order to remove
regularly plaque and calculus and also periodically revise the
oral health status of patient in-treatments [14–19, 25–27, 30–
52]. Thus, it is essential to programme a four-month follow-
up period for cancer patients in-treatment, without underes-
timating the contribution of the patient to the maintaining
of effective oral hygiene at home and the self-screening of
MRONJ[1, 4, 6, 14].
Dental prostheses in cancer patients in-treatment are
possible; notwithstanding that nowadays there are few recom-
mendations relating to this matter. Regarding the removable
dentures, it is fundamental to reduce the pressure of the
prosthesis on the oral mucosa and to maximize the stability,
in order to avoid possible chronical trauma of oral mucosa
[25, 53–56]. A four-month check-up period is desirable in
cancer patients with removable dental prostheses, the aim of
which is to constantly assess the fitting of the dentures and
the absence of any area of compression and/or pressure ulcer,
performing possible relining in soft resin, if needed [53–56].
Moreover, it is advisable that patients should not wear their
dentures for approximately 8–12 hours per day (at least during
the night).
Regarding the fixed prosthesis, it is important to pay
particular attention to the biological width, avoiding the
invasion of the junctional epithelium. Compatibly with the
aesthetic needs of the patient, it would be ideal to provide a
supragingival prosthetic margin, in order to facilitate check-
ups and oral hygiene at home [57]. Dental treatments in
cancer patients in the treatment phase are described in
Table 3.
6. Non-cancer Patients in Treatment Phase
The dental management of a non-cancer patient already
exposed to ONJ-related drugs is rather complex since it
correlates with assessing risk according to variable gradients.
These range from an undefined risk of MRONJ to a high risk
of developing MRONJ. Indeed, the specific risk of MRONJ
in the non-cancer patient varies according to the risk factors
present; coexistence of more drug-related, systemic, and/or
local risk factors is linked to various risk levels of MRONJ
[14, 58].
Non-cancer patients are supposed to be divided into two
categories regarding their risk to develop MRONJ; thereafter,
from 6 months to within 3 years from the commencing of
treatment, the patient who does not report other risk factors
(systemic and/or local) will be classified in Category A and
considered as a pre-treatment non-cancer patient at low risk
of MRONJ.
Different in nature and variable is the assessment per-
formed if the non-cancer patient has been in treatment for
a period of time greater than 3 years or shorter than 3
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years and simultaneously affected by systemic or local risk
factors (Category B) (see Table 5); this patient will bear
an incremental and indefinable risk of developing MRONJ,
which is linked to one or more additional, reported systemic
or local risk factors (see Table 6) [14, 17].
Surgical treatments (e.g., dental extractions, periodontal
or endodontic surgery) aimed at removing infective out-
breaks and the recovery of good oral health for Categories A
and B are indicated procedures [14].These procedures can be
performed for non-cancer patients in-treatment in Category
A, without applying specific medical and surgical protocols
[59]. However, it will be necessary to use precautions with
non-cancer patients in-treatment with Category B; these
are similar to those described for the cancer patient in-
treatment. For this reason, in patients in Category B, it
is desirable to perform invasive treatments in combination
with a prophylactic antibiotic therapy and to proceed tooth
by tooth, particularly when the ONJ-related drug has not
been suspended. Moreover, if available, it seems effective
in applying low-level laser therapy (e.g., laser Nd:YAG) and
APCs at the extraction site [32, 33]. After removing the
sutures, it is of the utmost importance to perform periodic
clinical-radiographic check-up (after 1, 3, 6, and 12 months)
[25].
Elective invasive dental procedures, such as implantol-
ogy and pre-implant bone surgery, in non-cancer patients
in-treatment are not considered explicitly contraindicated
but possible procedures, both for Categories A and B [60,
61]. Indeed, the risk/benefit ratio must be conscientiously
assessed with the patient, who will be informed of the not
definable risk of MRONJ: in the long term (e.g., risk of peri-
implantitis) for Category A patients and in the long and short
term (e.g., MRONJ related to the surgical procedures) for
Category B. However, alternative treatment would be advised
for patients included in Category B.
Promising results regarding the use of APCs during a
surgical implant procedure have recently been reported for
preventing MRONJ in non-cancer osteometabolic patients
in-treatment byMozzati et al., who have reported the absence
of the development of MRONJ in a retrospective study one
year after placing 1,267 implant placements on 235 patients,
combined with the use of APCs [62].
As for cancer patients in-treatment, invasive and non-
invasive dental treatments needed for the treatment of the
prevention or the removal of inflammatory or infective
lesions are mandatory in non-cancer patients in-treatments;
in addition, prosthetic rehabilitation should contemplate the
same recommendations [14, 25, 53–57].
Dental treatments of non-cancer patients in the in-
treatment phase are described in Table 3.
7. Drug Suspension/Holiday
Regarding the latter, there has been much discussion in the
literature about the validity of a temporary suspension of
ONJ-related drugs; the aim of this biological window is to
reduce the risk of an adverse event prior to surgical dental
procedure. The temporary suspension of the ONJ-related
drugs, the so-called drug holiday, must be compatible with
basic pathologies and authorized by the prescriber. Such a
suspension, when permitted, would be terminated preferably
once the soft tissue had healed. Up to date, there is no
scientific evidence which confirms the validity of the drug
holiday, whether the drug/s are administered intravenously
or orally, prior to the dental-alveolar surgery [1, 2, 5, 6, 14].
Specifically, the effects of BPs on the bone can be much
prolonged over time, even after a single administration. The
half-life of BPs is rather long, and they function by inhibiting
osteoclast function for an unknown period of time. It can be
hypothesized that suspending treatment could be associated
with a reduction in the antiangiogenic effect of BPs on the
periosteum and soft tissue [17, 63, 64]. This could contribute
to vascularization improvement and encourage more rapid
healing after surgery. Moreover, it could be useful in reducing
the concentration of intravenous BPs at the extraction site
in cancer patients, where their accumulation would increase
tropism where there is extensive bone remodeling. Further-
more, about cancer patients in-treatment, any drug holiday
should be considered to be a risky practice due to the possible
progression of the oncological pathology and the absence
of checking for bone-related events. In cancer patients in-
treatment with different drugs by BP, suspending those is a
desirable event. This will probably start from 7 days prior to
any planned intervention (except for the Bevacizumab that
should be suspended 6-7 weeks before), at least until the
mucosal healing of the post-extraction site (see Table 4).The
differing time periods are due to the fact that the well-
known half-life of various MRONJ-related drugs is different.
It is the experience of the authors that for the non-cancer
patient included in category B, a drug holiday can already
be considered useful one week before invasive dental pro-
cedures. However, this suspension is possible in cases where
significant bone disequilibrium has not resulted, as assessed
by the physician. BPs administration can resume 30–45 days
after suspension, when the mucosa at the surgical site has
healed (see Table 6). An interruption in BPs administration
evenmonths prior to surgery is suggested, where the systemic
conditions of the patient permit this, and treatment is to
be resumed after the total closing of any surgical wound.
This approach, however, is based purely on expert opinion
and it has not been yet validated in the literature. Since
the beneficial effects of BPs in controlling basic diseases
and related complications are well-known and while doubt
remains regarding a BPs suspension, the patient must always
be informed about the low predictability of such a suspension
effect and the possible risks connected to the exacerbation
of metabolic bone compensation. No drug suspension is
necessary for the non-cancer osteometabolic patient in-
treatmentwithDenosumab, given the latency period between
subsequent Denosumab administrations, namely, every 6
months. It is appropriate to perform invasive procedures after
4weeks from the lastDenosumab administration andno later
than the 6 weeks before the next administration, so as to
ensure an adequate healing period. Should it be necessary
to perform invasive procedures in a different time frame,
it is advisable that these are planned within and not more
than 45 days from subsequent administrations ofDenosumab
[6, 14, 52].
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Table 4: Drug suspension for cancer patients; it must be agreed upon with the oncologist and performed according to the table.
Drug holiday in cancer patients
Active pharmaceutical ingredient Last administration Resume treatment
Bisphosphonate (AR) At least 1 week before 4–6 weeks after
Denosumab (AR) At least 1 week before 4–6 weeks after
Bevacizumab (AA) At least 6-7 weeks before 4–6 weeks after
Sunitinib (AA) At least 1 week before 4–6 weeks after
Everolimus (AA) At least 1 week before 4–6 weeks after
Table 5: A classification of non-cancer patients already in treatment with MRONJ-related drugs.
Risk assessment of MRONJ in non-cancer patients
Category A Category B
(i) Patients eligible and not yet treated with ONJ-related
medication
(ii) Patients exposed to ONJ-related medication for less
than 3 years, in absence of other systemic risk factors
(i) Patients exposed to ONJ-relatedmedication for
more than 3 years
(ii) Patients exposed to ONJ-relatedmedication for less
than 3 years and in presence of other systemic risk
factors
(iii) Patients assuming BPs by IM∗
∗To date, there exists no data to distinguish groups of patients in treatment with zoledronate intravenous (annual medication intake) at greater or lesser risk
of developing MRONJ.
Table 6: Drug suspension for non-cancer patients; it must be agreed
upon with the prescriber and performed according to the table.
Drug holiday in non-cancer patients
Active
pharmaceutical
ingredient
Last administration Therapy resumption
Bisphosphonate∗
(AR)
1 week before 4–6 weeks after
Denosumab (AR) No suspension∗∗
∗Administered by more than three years or for less than three years and
in the presence of other systemic risk factors; ∗∗suspension is not needed
thanks to the latency between drug administrations. It is useful to perform
invasive procedures between the first and the third month from the last
administration, so as to ensure an adequate period for healing before the next
dose.
8. Conclusion
MRONJ is a rare but serious and highly debilitating disease
since it can significantly compromise the patient’s quality of
life and reduce the compliance of the patients to AR/AA
treatments. The number of cancer and non-cancer patients
being treated with ONJ-related drugs and, therefore, the
number of potentially adverse events seem constantly on the
increase, also on the light of newdrug related toONJ.Amulti-
disciplinary standardized approach with a sustained dialogue
among clinicians involved in the treatment of patients at risk
ofMRONJ should be adopted in order to improve the efficacy
of therapeutic strategies and to increase the patient’s quality
of life. The important role of the dentist in preventing the
MRONJ, checking the local risk factors of MRONJ in pre-
treatment and in-treatment patients, is evident.
Moreover, it is necessary to intervene in possible early
signs of MRONJ for the secondary prevention. The applica-
tion of such protocols of primary and secondary prevention,
together with the dentists actions, the clinicians’ sinergy,
and the adequate awareness of the patient, is the key to
implementing policies aimed at a common goal, that is, the
reduction in outbreaks of MRONJ.
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